Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis



Breast Cancer Market shows promising trends
About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime, according to Breast cancer organization. Moreover, the year 2019, an estimated 268,600 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 62,930 new cases of non-invasive (in situ) breast cancer. There are lots of risk factors that can cause Breast Cancer. Around 5-10% of the Breast cancer rates are hereditary and are caused by the transfer of abnormal genes to offspring. Most of the inherited cancers are caused due to the mutations in BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two).
Triple-negative breast cancer is a rare type of Breast cancer, affecting only about 10 to 20 percent of people with breast cancer. If a patient gets diagnose with Triple Negative Breast Cancer it certainly means the absence of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification/overexpression. DelveInsight’s estimates suggest that the diagnosed TNBC cases were highest with HER2- expression.
Breast Cancer Epidemiology
China accounts for 43% of the total Triple-negative Breast Cancer cases followed by the US which accounts for 24% of the total TNBC diagnosed incident cases, in G8 countries in 2016, observed DelveInsight, a Healthcare consulting firm. Moreover, the total Triple Negative Breast Cancer incident cases in the US were estimated to be around 30,285 in the year 2016.  
Breast cancer is also diagnosed in men, as in the year 2019, more than 2,600 men will be diagnosed with Breast cancer, and approximately 500 men will die from the disease.
Breast Cancer Market
Triple-negative breast cancer is one of the most difficult cancer to treat mainly because of fewer marketed therapies. Currently, the therapeutic market size of mTNBC in the United States is mainly accounted by the systemic chemotherapies (either alone or in combination), such as Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel etc.
In the year 2018, Lynparza (Olaparib) developed by AstraZeneca, became the first non-chemotherapy treatment for patients with an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer, to receive the U.S. Food and Drugs Administration (USFDA) approval. Although the drug is not specifically approved for TNBC patients, it still provides a novel treatment option for mTNBC patients with BRCA mutation, as per DelveInsight’s analysts.
DelveInsight estimates that Triple Negative Breast Cancer therapeutic market for in G8 Countries is expected to increase by 2027, at a CAGR of 18.9% for the study period 2016-2027. The United States accounted for 33% of the total sales in 2016 and is expected to occupy 37% of the total market by 2027.

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more